After Watershed Year, Pfizer Expects Revenue to Top $98B in ’22
Summary : Pfizer Chief Executive Officer Albert Bourla called 2021 a watershed year for the company. It posted $81.3 billion in revenue…
Summary : Pfizer Chief Executive Officer Albert Bourla called 2021 a watershed year for the company. It posted $81.3 billion in revenue…
Summary : The U.S. Food and Drug Administration approved Sanofi’s proposed drug to address red blood cell destruction in patients living with…
Summary : A good news is brewing for kids as the COVID-19 vaccine for the age group younger than 5 years old…
Summary : FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease Enjaymo is the only approved treatment…
Synopsis : Sanofi has been a global healthcare leader that has brought forth treatments for rare diseases and established standard-of-care therapeutics for…
Synopsis : Novartis reported its full-year financials this week for 2021, and overall, the news was good. Full-year net sales grew 4%,…
Summary – The House Energy and Commerce Committee’s health panel met to discuss renewing user fee agreements used to fund the U.S.…
Synopsis : Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported further positive…
Synopsis : A $1.5 billion diabetes partnership between Eli Lilly and China-based Regor Therapeutics Group is at the center of a lawsuit…
Summary : This week, Gilead Sciences took a $1.25 billion hit after reaching a settlement with ViiV Healthcare on a patent dispute…